Drugs in the Pipeline: What’s Next and the Science Behind It
The biology of Alzheimer’s is complex. This session will cover the latest research at the heart of the amyloid hypothesis, how each new drug in this class is different, and what other innovative solutions are being explored. Key Question: What should all of Us know as we face a disease with very limited treatment options today?
Prioritizing Early Detection: What’s Needed, What’s Working, and How We Can Ensure Everyone Has Access
Although Black and Latino older adults are more likely to develop Alzheimer’s and dementia, diagnoses are more likely to be missed or delayed for people in these groups. Lumping together all people of color with a “one size fits all” approach is not the solution. These disparities stem from a complex set of factors including systemic racism, historic marginalization, cost, and more. Key Question: How can all of Us drive brain health awareness, risk reduction, and early detection—especially in Black and Latino communities?
Beyond Contemplating the Challenge of Inclusion in Clinical Trials
Clinical trials have traditionally fallen short when it comes to including people who are truly representative of the Alzheimer’s population. Recently successful efforts, however, are dispelling myths about the inclusion challenge. For example, among the 389 participants in the Evaluating Minority Patients with Actemra (EMPACTA) study approximately 84% were from Black, Hispanic, Native American, and other historically underrepresented groups. Key Question: What strategies successfully recruit, enroll, and retain participants who represent all of Us, especially those disproportionately affected?
Holly A. Massett
Fireside Chat with U.S. Representative Anna G. Eshoo and George Vradenburg
The creation of the new Advanced Research Projects Agency for Health, or ARPA-H, is a huge victory in the fight against Alzheimer’s and other diseases affecting millions of people nationwide. We ask one of its champions what needs to happen from a legislative and regulatory perspective to ensure the agency hits the ground running in 2023 and to maximize its potential to achieve a breakthrough in ending Alzheimer’s.